Polyneuropathy Clinical Trial
Official title:
Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy
Polyneuropathy associated with anti-MAG monoclonal IgM gammopathy is responsive of mainly a sensory deficit in predominantly males ,aged 40-70 years. Significantly high serum anti-MAG antibodies are linked with demyelinating features of the peripheral nerves.Rituximab, an anti-CD 20 monoclonal antibody is a new drug which reduces B-lymphocytes. This study will test the safety and efficacy of rituximab in the treatment of patients with anti-MAG polyneuropathy.
Acting of a polyneuropathy for which there is not any treatment of reference today (see
supra), a test of double-knowledge versus placebo is justified. Acting of a chronic
polyneuropathy, the clinical evaluation must be led over one one year period. Acting of a
sensitive polyneuropathy and the awaited benefit being the IMPROVEMENT OF the CLINICAL
SIGNS, the principal criterion is a sensitive score in addition validated in chronic
sensitive polyneuropathies immunodeficiency syndrome.
The patients answering the criteria of inclusion and none inclusion (see V-2) will be
randomized in 2 groups: the first group will receive a perfusion IV of rituximab to the
amount of 375 mg/m2 of body surface, once per week, during 4 weeks (see VII-3); the second
group will receive 4 perfusions IV of placebo according to same methods'. The evaluation
(see VI-1) will be carried out at the time of the randomization, then repeated in 3 months,
6 months, 9 months and 1 year.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05560555 -
Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.
|
||
| Recruiting |
NCT02033057 -
Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences.
|
Phase 4 | |
| Withdrawn |
NCT02566941 -
Neuromuscular Electrical Stimulation in the Critically Ill
|
N/A | |
| Completed |
NCT02442986 -
Neurological Outcome in Surgical and Non-surgical Septic Patients
|
N/A | |
| Completed |
NCT02706314 -
Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.
|
||
| Completed |
NCT01076478 -
Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines
|
Phase 4 | |
| Completed |
NCT03373370 -
Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology
|
||
| Completed |
NCT02846844 -
Patients With Chemotherapy-induced Polyneuropathy Are Treated With an Integrated Program Including Massage, Mobilization in Posture and Transport Layers, Physical Exercises or With Whole-body Vibration Platform Training
|
N/A | |
| Recruiting |
NCT05950867 -
Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.
|
N/A | |
| Terminated |
NCT00832572 -
Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy
|
Phase 4 | |
| Completed |
NCT00614562 -
Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)
|
Phase 1 | |
| Terminated |
NCT01088256 -
Efficacy of Etoricoxib on Peripheral Hyperalgesia
|
Phase 2 | |
| Completed |
NCT01302275 -
Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain
|
Phase 4 | |
| Not yet recruiting |
NCT01047488 -
Imipramine and Pregabalin Combination in Painful Polyneuropathy
|
Phase 4 | |
| Completed |
NCT04201418 -
A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
|
||
| Completed |
NCT01450163 -
Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy
|
Phase 3 | |
| Recruiting |
NCT05040373 -
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
|
||
| Not yet recruiting |
NCT02666456 -
The Influence of Sensory Phenotype on the Risk of Developing Neuropathic Pain
|
N/A | |
| Withdrawn |
NCT00723918 -
Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy
|
Phase 2 |